CD274 and sarcoma: Apart from the promising results of these two studies (Table 2), the CONGRATS study (NCT04095208), still recruiting, includes STS patients with a sarcoma enriched with TLS, evaluating treatment with nivolumab, anti-PDL1, which is associated with anti-LAG3, and relatlimab.